1. Hernández-Jiménez J, Martínez-Ortega A, Salmerón-García A, Cabeza J, Prados JC, Ortíz R, Navas N. Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles. Int J Biol Macromol. 2018 Oct 15;118(Pt A):511-524.
2. Clinical development of targeted and immune based anti-cancer therapies. Seebacher NA, Stacy AE, Porter GM, Merlot AM. J Exp Clin Cancer Res. 2019 Apr 11;38(1):156
3. Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. Abu-Shawer O, 3. Bushnaq T, AbuShawer M. Gulf J Oncolog. 2019 Jan;1(29):76-82
4. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. Birrer MJ, Moore KN, Betella I, Bates RC. J Natl Cancer Inst. 2019 Mar 11. pii: djz035. doi: 10.1093/jnci/djz035.
5. A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next? Perwein MK, Smestad JA, Warrington AE, Heider RM, Kaczor MW, Maher LJ , Wootla B, Kunbaz A, Rodriguez M. Expert Opin Biol Ther. 2018, 18(5):545-560.
6. Discovery and design of self-assembling peptides. Zhang S. Interface Focus. 2017, 7(6):20170028
7. Antibody Administration for Bone Tissue Engineering: A Systematic Review. Hosseinpour S, Rad MR, Khojasteh A, Zadeh HH. Curr Stem Cell Res Ther. 2018;13(4):292-315.
8. Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects.. Khojasteh A, Hosseinpour S, Dehghan MM, Mashhadiabbas F, Rezai Rad M, Ansari S, Farzad Mohajeri S, Zadeh HH. Biomed Res Int. 2018 Feb 28;2018:9508721.
9. New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells. O'Brien CM, Chy HS, Zhou Q, Blumenfeld S, Lambshead JW, Liu X, et al. Stem Cells. 2017, 35(3):626-640.
10. Immunotherapy strategies for spinal cord injury. Wang YT, Lu XM, Chen KT, Shu YH, Qiu CH. Curr Pharm Biotechnol. 2015;16(6):492- 505
11. Christian D. Adams Sánchez (2016). Anticuerpos Monoclonales en medicina cardiovascular: Principios inmunlógicos y terapéuticos de la terapia biológica en cardiología y medicina interna. Editorial Enseñanza Española.
12. Overcoming immunological barriers in regenerative medicine. Zakrzewski JL, van den Brink MR, Hubbell JA. Nat Biotechnol. 2014 Aug;32(8):786-94
13. Anti-HLA antibodies in regenerative medicine stem cell therapy. Dominique Charron, Caroline Suberbielle-Boissel, Ryad Tamouza, Reem Al-Daccak. Human Immunology, 2016, 73,1287-1294.
14. Effects of the orientation of anti-BMP2 monoclonal antibody immobilized on scaffold in antibody-mediated osseous regeneration. Ansari S, Freire M, Choi MG, Tavari A, Almohaimeed M, Moshaverinia A, Zadeh HH. J Biomater Appl. 2015 Nov;30(5):558-67.
15. A view on EGFR-targeted therapies from the oncogene-addiction perspective. Perez R, Crombet T, de Leon J, Moreno E. Front Pharmacol2013, 4, 53
16. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Steiner M, Neri D. (2011).. Clin Cancer Res. 17(20):6406-16.
1. History of monoclonal antibodies and lessons for the development of stem cell therapeutics. Alain A. Vertès Nasib Qureshi Arnold I. Caplan Lee E. Babiss Editor(s). Wiley Online Library. 2016.
2. Current Developments in Biotechnology and Bioengineering. Vanete Thomaz-Soccol, Ashok Pandey, Rodrigo R. Resende Editor (s).Elseviere. 2017.
3. Human monoclonal antibodies. Methods and Protocols. Michael Steinitz Editor(s). Springer. 2016
